SG11201808774RA - Treatment of renal cell carcinoma with lenvatinib and everolimus - Google Patents

Treatment of renal cell carcinoma with lenvatinib and everolimus

Info

Publication number
SG11201808774RA
SG11201808774RA SG11201808774RA SG11201808774RA SG11201808774RA SG 11201808774R A SG11201808774R A SG 11201808774RA SG 11201808774R A SG11201808774R A SG 11201808774RA SG 11201808774R A SG11201808774R A SG 11201808774RA SG 11201808774R A SG11201808774R A SG 11201808774RA
Authority
SG
Singapore
Prior art keywords
international
lenvatinib
everolimus
april
pct
Prior art date
Application number
SG11201808774RA
Other languages
English (en)
Inventor
Alton Kremer
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of SG11201808774RA publication Critical patent/SG11201808774RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201808774RA 2016-04-15 2017-04-17 Treatment of renal cell carcinoma with lenvatinib and everolimus SG11201808774RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322916P 2016-04-15 2016-04-15
JP2016081787 2016-04-15
PCT/JP2017/015461 WO2017179739A1 (fr) 2016-04-15 2017-04-17 Traitement du carcinome à cellules rénales à l'aide de lenvatinib et d'évérolimus

Publications (1)

Publication Number Publication Date
SG11201808774RA true SG11201808774RA (en) 2018-11-29

Family

ID=60041779

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808774RA SG11201808774RA (en) 2016-04-15 2017-04-17 Treatment of renal cell carcinoma with lenvatinib and everolimus

Country Status (7)

Country Link
EP (1) EP3442532A4 (fr)
KR (1) KR20180129795A (fr)
CN (1) CN108883106A (fr)
AU (1) AU2017249459A1 (fr)
CA (1) CA3019682A1 (fr)
SG (1) SG11201808774RA (fr)
WO (1) WO2017179739A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109793736A (zh) * 2019-01-31 2019-05-24 徐州医科大学 一种乐伐替尼在制备自然杀伤细胞激动剂中的应用
AU2021297151A1 (en) * 2020-06-17 2023-02-09 Eisai R&D Management Co., Ltd. Methods for treating cancer or von-Hippel Lindau disease using a combination of a PD-1 antagonist, a HIF-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1698623T3 (pl) * 2003-12-25 2015-08-31 Eisai R&D Man Co Ltd Postać krystaliczna soli 4-(3-chloro-4-(cyklopropyloaminokarbonylo)aminofenoksy)-7-metoksy-6-chinolinokarboksamidu lub jej solwatu i sposoby ich wytwarzania

Also Published As

Publication number Publication date
KR20180129795A (ko) 2018-12-05
CA3019682A1 (fr) 2017-10-19
EP3442532A1 (fr) 2019-02-20
EP3442532A4 (fr) 2019-12-11
WO2017179739A1 (fr) 2017-10-19
AU2017249459A1 (en) 2018-10-25
CN108883106A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
SG11201805888SA (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201809132RA (en) Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
SG11201805120YA (en) Zika virus vaccine
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201804312RA (en) Microbubble-chemotherapeutic agent complex for sonodynamic therapy
SG11201808125RA (en) Methods for solid tumor treatment
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201901501UA (en) Compositions and methods for enhancing cancer radiotherapy
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201810192TA (en) Antibacterial compositions
SG11201811209QA (en) Oral gastroretentive formulations and uses thereof
SG11201807963WA (en) Compositions useful in the prevention and/or treatment of disorders of the oral cavity, upper airways and esophagus
SG11201811686UA (en) 18f-labeled triazole containing psma inhibitors
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201804885TA (en) Monomaleimide-functionalized platinum compounds for cancer therapy
SG11201900043TA (en) Antibody formulations
SG11201909359YA (en) Pharmaceutical composition comprising pde9 inhibitor
SG11201901689YA (en) Compounds for treating diseases associated with a mitochondrial dysfonction
SG11201810934TA (en) Microparticles comprising a sulphur-containing compound
SG11201900214UA (en) Iso-citrate dehydrogenase (idh) inhibitor